ArticleHealth science reports2025
Role of Angiotensin Receptor Blockers on Cardiovascular Protection in Marfan Syndrome: A Literature Review.
Article in Health science reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Role of Angiotensin Receptor Blockers on Cardiovascular Protection in Marfan Syndrome: A Literature Review.Health science reports · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Aims: Marfan Syndrome (MFS) is a hereditary connective tissue disorder with severe cardiovascular complications, including aortic aneurysms and dissections. Current therapies, such as beta-blockers, have limitations in preventing disease progression. Angiotensin receptor blockers (ARBs) have emerged as a potential therapy due to their modulation of the renin-angiotensin-aldosterone system. This review evaluates the evidence of ARBs' cardiovascular benefits in MFS, focusing on their effects on aortic root dilation, stiffness, and clinical outcomes. Methods: A review of literature published between January 2000 and June 2024 was conducted using databases like PubMed, Scopus, Web of Science, and Cochrane Library. Search terms included "Marfan Syndrome," "Angiotensin Receptor Blockers," and "cardiovascular outcomes." Studies assessing the efficacy and safety of ARBs in MFS were included, with their findings summarized descriptively. Results: Preclinical studies demonstrated ARBs' effectiveness in reducing aortic root dilation and stiffness in murine models of MFS. Clinical trials highlighted losartan's ability to slow aortic root dilation in adults and children, with synergistic effects when combined with beta-blockers. Despite promising results, variability in study designs and dosage regimens limited comparability. A systematic review noted significant TGF-β inhibition-related improvements in pediatric patients. However, long-term safety and optimal dosing require further exploration. Conclusion: ARBs show promise in mitigating cardiovascular complications in MFS by reducing aortic root dilation and improving vascular function. Further research is essential to determine optimal dosing, long-term efficacy, and combination therapy potential, paving the way for personalized management strategies to improve patient outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.